The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2014Disease-modifying Chemical Probes to Inhibit Alpha-synuclein Aggregation
Objective/Rationale:
There is a great need to discover novel therapeutic targets and strategies that halt or reverse the progression of Parkinson’s disease (PD). In this study we hope to... -
Repositioning Drugs for PD, 2014DPP-4 Inhibitors for the Treatment of Parkinson’s Disease (Supplement)
Promising Outcomes of Original Grant:
Dipeptidyl protease-4 (DPP-4) inhibitors are widely used in the effective treatment of type 2 diabetes to safely regulate blood glucose levels. DPP-4 is the key... -
Research Grant, 2014Chemical Modulator of Chaperone-mediated Autophagy in Parkinson's Disease
Objective/Rationale:
Brain cells depend on very efficient surveillance systems to identify defective components and break them apart to avoid accumulation and toxicity. We have found that in the brain... -
Rapid Response Innovation Awards, 2014Impact of the Medical Food ErgoD2® on Alpha-synuclein and Iron Levels
Objective/Rationale:
Although the causes of Parkinson’s disease (PD) are yet unknown, the overall health of the body likely plays a major role in disease initiation and progression... -
Therapeutic Pipeline Program, 2014Evaluating the Safety, Tolerability and Efficacy of SYN120 in Parkinson’s Disease Dementia
Study Rationale:
Cognitive impairments — common in Parkinson’s disease — are associated with an imbalance in neurotransmitters (substances that allow nerve cells to communicate with one another) such... -
Research Grant, 2014Efficacy and Safety of APL-130277 in People with Parkinson’s Disease who are Apomorphine Naïve
Study Rationale:
Apomorphine is a drug that is used to control “off” episodes in people with Parkinson’s disease. At present, the drug is given by injection under the skin and starts...
![Two female doctors talking in the lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/apply-for-grant-404-Large-Image-Callout-A-1.jpg?h=2a1ad497&itok=-_5jZ5iX)
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.